A Phase 2 interventional study of Travoprost 0.004% and Travoprost Vehicle in Open-angle Glaucoma (OAG) and Ocular Hypertension, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-23.
Sponsored by Alcon Research (part of Alcon) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 33rd largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2010, is one of 6 in phase 2, and was the 24th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Jonathon Myers · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 135 across the 45 interventional studies. Of the 43 that completed or were terminated, 23 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 46 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 88th largest by enrollment of the 112 interventional ones that give a count, is one of 7 that started in 2010, is one of 33 in phase 2, and was the 61st registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
meets the following IOP entry criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TRAVATAN 0.004% once daily
Drug: Travoprost 0.004%
Travoprost Vehicle
Drug: Travoprost Vehicle
Travoprost Group A
Drug: Travoprost (Groups A, B and C)
Travoprost Group B
Drug: Travoprost (Groups A, B and C)
Travoprost Group C
Drug: Travoprost (Groups A, B and C)
1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days
1 drop in each eye 8 times daily for 5 days
Drug page: Travoprost
1 drop in each eye 8 times daily for 5 days
Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5
Outcome measure shows how each treatment reduced eye pressure at 8 AM on Day 5 compared to the eye pressure at 8 AM before the start of treatment
Time frame: 5 days
IOP Change From Baseline at 8 PM on Day 5
Outcome measure shows how each treatment reducted eye pressure at 8 PM on Day 5 compared to the eye pressure at 8 PM before the start of treatment
Time frame: 5 Days
| Milestone | TRAVATAN | Travoprost Vehicle | Travoprost Group A | Travoprost Group B | Travoprost Group C |
|---|---|---|---|---|---|
| Started | 14 | 14 | 14 | 13 | 12 |
| Completed | 14 | 14 | 14 | 13 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Outcome measure shows how each treatment reduced eye pressure at 8 AM on Day 5 compared to the eye pressure at 8 AM before the start of treatment
| mm Hg | Travatan 0.004% QD | Travoprost Vehicle | Travoprost Group A | Travoprost Group B | Travoprost Group C |
|---|---|---|---|---|---|
| Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5 | -9.8 (-12.5 to -7.0) | -2.9 (-4.7 to -1.0) | -5.0 (-6.7 to -3.3) | -6.5 (-8.7 to -4.4) | -6.8 (-8.5 to -5.0) |
Outcome measure shows how each treatment reducted eye pressure at 8 PM on Day 5 compared to the eye pressure at 8 PM before the start of treatment
| mm Hg | Travatan 0.004% QD | Travoprost Vehicle | Travoprost Group A | Travoprost Group B | Travoprost Group C |
|---|---|---|---|---|---|
| IOP Change From Baseline at 8 PM on Day 5 | -3.9 (-6.2 to -1.5) | -0.9 (-2.6 to 0.7) | -2.7 (-4.3 to -1.2) | -5.7 (-7.5 to -3.9) | -4.8 (-6.1 to -3.6) |
Collected over 1 month. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TRAVATAN | — | 0/14 (0%) | 8/14 (57.1%) |
| Travoprost Vehicle | — | 0/14 (0%) | 2/14 (14.3%) |
| Travoprost Group A | — | 0/14 (0%) | 5/14 (35.7%) |
| Travoprost Group B | — | 0/13 (0%) | 8/13 (61.5%) |
| Travoprost Group C | — | 0/12 (0%) | 6/12 (50%) |
| Event | TRAVATAN | Travoprost Vehicle | Travoprost Group A | Travoprost Group B | Travoprost Group C |
|---|---|---|---|---|---|
| Ocular HyperaemiaEye disorders | 4/14 | 0/14 | 5/14 | 5/13 | 5/12 |
| PhotophobiaEye disorders | 0/14 | 0/14 | 0/14 | 3/13 | 0/12 |
| Eye PruritusEye disorders | 2/14 | 1/14 | 1/14 | 2/13 | 0/12 |
| Vision BlurredEye disorders | 0/14 | 0/14 | 0/14 | 0/13 | 1/12 |
| Corneal StainingEye disorders | 1/14 | 1/14 | 1/14 | 0/13 | 1/12 |
| Dry EyeEye disorders | 1/14 | 0/14 | 1/14 | 1/13 | 0/12 |
| Eye IrritationEye disorders | 0/14 | 0/14 | 0/14 | 1/13 | 0/12 |
| Foreign Body SensationEye disorders | 1/14 | 0/14 | 0/14 | 0/13 | 0/12 |
| HeadacheEye disorders | 1/14 | 0/14 | 0/14 | 0/13 | 0/12 |
| Age, Categorical(Participants) | TRAVATAN | Travoprost Vehicle | Travoprost Group A | Travoprost Group B | Travoprost Group C | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 8 | 9 | 4 | 3 | 32 |
| >=65 years | 6 | 6 | 5 | 9 | 9 | 35 |
| Sex: Female, Male(Participants) | TRAVATAN | Travoprost Vehicle | Travoprost Group A | Travoprost Group B | Travoprost Group C | Total |
|---|---|---|---|---|---|---|
| Female | 7 | 7 | 6 | 9 | 8 | 37 |
| Male | 7 | 7 | 8 | 4 | 4 | 30 |
The record gives a start of Apr 2010 and a primary completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost